NR4A1 Antagonists Inhibit β1-Integrin-Dependent Breast Cancer Cell Migration by Hedrick, Erik et al.
1 
 
NR4A1 Antagonists Inhibit β1-Integrin-Dependent Breast Cancer Cell 1 
Migration 2 
 3 
Erik Hedrick1, Syng-Ook Lee2, Ravi Doddapaneni3, Mandip Singh3 and Stephen Safe1# 4 
 5 
1 Department of Veterinary Physiology and Pharmacology, Texas A&M University, College 6 
Station, TX  77843-4466 7 
 8 
2 Department of Food Science and Technology, Keimyung University, Daegu 704701, Republic 9 
of Korea 10 
 11 
3 Department of Pharmaceutics, College of Pharmacy and Pharmaceutical Sciences, Florida 12 
A&M University, Tallahassee, FL  32307 13 
 14 
 15 
Running Title:  β1-Integrin can be targeted by NR4A1 antagonists 16 
 17 
 18 
Key Words:  NR4A1 antagonists, C-DIMs, B1-integrin, B3-integrin, cell migration 19 
 20 
 21 
 22 
# To whom correspondence should be addressed:  Stephen Safe, Department of Veterinary 23 
Physiology and Pharmacology, Texas A & M University, 4466 TAMU, College Station, TX 24 
77843-4466  USA, Tel: 979-845-5988/Fax: 979-862-4929, Email: ssafe@cvm.tamu.edu 25 
 26 
  27 
MCB Accepted Manuscript Posted Online 29 February 2016
Mol. Cell. Biol. doi:10.1128/MCB.00912-15
Copyright © 2016, American Society for Microbiology. All Rights Reserved.
 o
n
 Septem
ber 12, 2018 by guest
http://m
cb.asm
.org/
D
ow
nloaded from
 
 o
n
 Septem
ber 12, 2018 by guest
http://m
cb.asm
.org/
D
ow
nloaded from
 
 o
n
 Septem
ber 12, 2018 by guest
http://m
cb.asm
.org/
D
ow
nloaded from
 
2 
 
Abstract:   28 
 Overexpression of the nuclear receptor 4A1 (NR4A1) in breast cancer patients is a 29 
prognostic factor for decreased survival and increased metastasis and this has been linked to 30 
NR4A1-dependent regulation of TGFβ signaling.  Results of RNA interference studies 31 
demonstrate that basal migration of aggressive SKBR3 and MDA-MB-231 breast cancer cells is 32 
TGFβ-independent and -dependent on regulation of β1-integrin gene expression by NR4A1 33 
which can be inhibited by the NR4A1 antagonists 1,1-bis(3'-indolyl)-1-(p-34 
hydroxyphenyl)methane (DIM-C-pPhOH) and a related p-carboxymethylphenyl (DIM-C-35 
pPhCO2Me) analog.  The NR4A1 antagonists also inhibited TGFβ-induced migration of MDA-36 
MB-231 cells by blocking nuclear export of NR4A1 which is an essential step in TGFβ-induced 37 
cell migration.  We also observed that NR4A1 regulates expression of both β1- and β3-integrins 38 
and unlike other β1-integrin inhibitors which induce prometastatic β3-integrin, NR4A1 39 
antagonists inhibit expression of both β1- and β3-integrin demonstrating a novel mechanism-40 
based approach for targeting integrins and integrin-dependent breast cancer metastasis. 41 
 42 
 43 
 44 
  45 
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Introduction 46 
 Cell adhesion and attachment are essential for tissue integrity and cellular homeostasis, 47 
and the heterodimeric integrin cell surface receptors play a critical role in these processes (1-3).  48 
There are 18 different α and 8 different β subunits that form 24 αβ-integrin receptor 49 
heterodimers, and the large 12-member β1-integrin sub-group bind multiple extracellular matrix 50 
(ECM) molecules to activate multiple intracellular pathways and also induce crosstalk with other 51 
signaling systems (1-3).  The functions of integrin heterodimers are highly tissue-specific, and 52 
many human pathologies also involve integrin signaling (reviewed in 4, 5).  β1-Integrin is highly 53 
expressed in most tumors and is associated with a negative prognostic significance such as 54 
overall and disease-free survival, recurrence, and metastasis for head and neck and squamous 55 
cell carcinoma, melanoma, lung, breast, prostate, laryngeal and pancreatic cancers (6-17).  A 56 
recent immunostaining study of 225 breast invasive ductal carcinomas (IDCs) showed that β1-57 
integrin was overexpressed in 32.8% of patients with IDCs (13).  Numerous studies show that 58 
focal adhesion kinase (FAK) which is downstream from β1-integrin is also a negative prognostic 59 
factor for breast cancer patients (18-20).  The important functional role of β1-integrin has been 60 
demonstrated in mouse models expressing erbB2 under the control of the mouse mammary 61 
tumor virus and crossed with mammary tissue-specific β1-integrin-deficient mice.  These mice 62 
exhibit a decrease in tumor volume, increased apoptosis and decreased lung metastasis compared 63 
to animals expressing wild-type β1-integrin (21-23).  Although small molecules, peptides and 64 
antibodies that inhibit β1-integrin signaling have been developed, clinical application of agents 65 
that target β1-integrin for cancer chemotherapy are not currently available.   66 
 The orphan nuclear receptor 4A1 (NR4A1, TR3, Nur77) is overexpressed in breast 67 
cancer and other tumors, and functional studies show that NR4A1 exhibits pro-oncogenic 68 
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activity (reviewed in 24).  Studies in this laboratory have characterized a series of 1,1-bis(3'-69 
indolyl)-1-(p-substituted phenyl)methane (C-DIM) analogs that bind NR4A1 and act as receptor 70 
antagonists to inhibit growth and induce apoptosis in several cancer cell lines and in tumors from 71 
mouse xenografts (25-30).  A recent study demonstrated functional interactions between NR4A1 72 
and TGFβ and in estrogen receptor (ER)-negative MDA-MB-231 cells, knockdown of NR4A1 73 
decreased migration and also inhibited TGFβ-induced migration of this cell line (31).  Results of 74 
gene array studies in pancreatic cancer cells identified β1-integrin as a potential NR4A1-75 
regulated gene (27).  In this study, we demonstrate that NR4A1 regulates β1-integrin expression 76 
and β1-integrin-dependent migration of breast cancer cells and this is accompanied by decreased 77 
expression of β3-inegrin.  In MDA-MB-231 cells, results of our studies show that both 78 
constitutive and TGFβ-induced migration are dependent on nuclear and extranuclear NR4A1-79 
regulated pathways, respectively.  C-DIM/NR4A1 antagonists inhibit NR4A1-dependent 80 
expression of β1- and β3-integrins and other pro-oncogenic NR4A1-regulated genes and 81 
pathways and represent a novel class of mechanism-based anticancer agents. 82 
 83 
Materials and Methods 84 
Cell lines and antibodies 85 
 SKBR3, MDA-MB-231 and MCF-7 breast cancer cells were purchased from American 86 
Type Culture Collection (Manassas, VA).  Cells were maintained 37°C in the presence of 5% 87 
CO2 in Dulbecco’s modified Eagle’s medium/Ham’s F-12 medium with 10% fetal bovine serum 88 
with antibiotic.  NR4A1 antibody was purchased from Novus Biologicals (Littleton, CO).  TGFβ 89 
was purchased from BD Biosystems (Bedford, MA).   β-Actin antibody, Dulbecco’s Modified 90 
Eagle’s Medium, PMI-1640 Medium, and 36% formaldehyde were purchased from Sigma-91 
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Aldrich (St. Louis, MO).  Hematoxylin was purchased from Vector Laboratories (Burlingame, 92 
CA).  β3-Integrin, p-FAK, FAK, Axin2, leptomycin B, and NR4A1 immunofluorescent antibody 93 
were purchased from Cell Signaling Technologies (Manassas, VA).  β1-Integrin antibody was 94 
purchased from Santa Cruz Biotech (Santa Cruz, CA), p84 antibody from GeneTex (Irvine, CA), 95 
and GAPDH antibody from Biotium (Hayward, CA). 96 
 97 
Cell adhesion assay 98 
 SKBR3, MDA-MB-231, and MCF-7 cancer cells (3.0 x 105 per well) were seeded in 99 
Dulbecco’s modified Eagle’s medium/Ham’s F-12 medium supplemented with 2.5% charcoal-100 
stripped fetal bovine serum and were allowed to attach for 24 hours.  Cells were seeded and 101 
subsequently treated with varying concentrations of DIM-C-pPhOH or DIM-C-pPhCO2Me for 102 
24 hours or 1 hour prior (± TGFβ [5 ng/ml], 4 hours cotreatment) or with 100 nm of siβ1-103 
integrin or siNR4A1 for 48 hours.  Cells were trypsinized, counted, and then placed for 90 min 104 
on BD BioCoat Human Fibronectin Cellware 24-well plates (Bedford , MA); medium was then 105 
aspirated, wells gently washed with PBS, and stained with 0.5% Crystal Violet Stain.  Cells were 106 
then counted for adhesion to fibronectin.  Wells coated with BSA and poly-L-lysine were used as 107 
negative controls. 108 
 109 
Boyden chamber assay 110 
 SKBR3, MDA-MB-231, and MCF-7 cancer cells (3.0 x 105 per well) were seeded in 111 
Dulbecco’s modified Eagle’s medium/Ham’s F-12 medium supplemented with 2.5% charcoal-112 
stripped fetal bovine serum and were allowed to attach for 24 hours.  Cells were seeded and 113 
subsequently treated with varying concentrations of DIM-C-pPhOH or DIM-C-pPhCO2Me for 114 
 o
n
 Septem
ber 12, 2018 by guest
http://m
cb.asm
.org/
D
ow
nloaded from
 
6 
 
24 hours or 1 hour prior (± TGFβ [5 ng/ml], 4 hours cotreatment) or with 100 nM of siβ1-115 
integrin, siNR4A1, siSp1 or sip300 for 48 hours.  Cells were trypsinized, counted, then placed in 116 
24-well 8.0 μm pore ThinCerts from BD Biosciences (Bedford, MA), allowed to migrate for 24 117 
hours, fixed with formaldehyde, and then stained with hematoxylin.  Cells that migrated through 118 
the pores were then counted.   119 
 120 
Real time PCR 121 
 RNA was isolated using Zymo Research Quick-RNA MiniPrep kit (Irvine, CA).  122 
Quantification of mRNA (β1-integrin, β3-integrin) was performed using Bio-Rad iTaq Universal 123 
SYBER Green 1-Step Kit (Richmond, CA) using the manufacturer’s protocol with real-time 124 
PCR.  TATA Binding Protein (TBP) mRNA was used as a control to determine relative mRNA 125 
expression. 126 
 127 
Immunoprecipitation 128 
 MDA-MB-231 cancer cells (3.0 x 105 per well) were seeded in Dulbecco’s modified 129 
Eagle’s medium/Ham’s F-12 medium supplemented with 2.5% charcoal-stripped fetal bovine 130 
serum and were allowed to attach for 24 hours. The medium was then changed to DMEM/Ham 131 
F-12 medium containing 2.5% charcoal-stripped fetal bovine serum, and either DMSO or TGFβ 132 
(5 ng/ml) was added for 4 hours (after ± pretreatment with leptomycin B (20 nM) for 24 hours or 133 
± pretreatment with 20 μM DIM-C-pPhOH or DIM-C-pPhCO2Me.  Protein A Dynabeads were 134 
prepared and binding of antibody with protein and protein-protein interactions were isolated by 135 
Life technologies Immunoprecipitation Kit using Dynabeads coated with Protein A (Grand 136 
 o
n
 Septem
ber 12, 2018 by guest
http://m
cb.asm
.org/
D
ow
nloaded from
 
7 
 
Island, NY) following manufacturer’s protocol.  Protein-protein interactions of interest were 137 
determined by western blot analysis. 138 
 139 
Chromatin immunoprecipitation 140 
 The chromatin immunoprecipitation (ChIP) assay was performed using the ChIP-IT 141 
Express magnetic chromatin immunoprecipitation kit (Active Motif, Carlsbad, CA) according to 142 
the manufacturer's protocol.  SKBR3 and MDA-MB-231 cells were treated with DMSO, DIM-143 
C-pPhOH, or DIM-C-pPhCO2Me (15 or 20 µM) for 24 hours.  Cells were then fixed with 1% 144 
formaldehyde, and the cross-linking reaction was stopped by addition of 0.125 M glycine.  After 145 
washing twice with phosphate-buffered saline, cells were scraped and pelleted.  Collected cells 146 
were hypotonically lysed, and nuclei were collected.  Nuclei were then sonicated to the desired 147 
chromatin length (∼200 to 1,500 bp).  The sonicated chromatin was immunoprecipitated with 148 
normal IgG, p300 (Santa Cruz), siSp1 (Abcam), NR4A1 (Novus Biologicals), or RNA 149 
polymerase II (pol II; Active Motif) antibodies and protein A-conjugated magnetic beads at 4°C 150 
for overnight.  After the magnetic beads were extensively washed, protein-DNA cross-links were 151 
reversed and eluted.  DNA was prepared by proteinase K digestion followed by PCR 152 
amplification.  The primers for detection of the β1-integrin promoter region were 5'–153 
TCACCACCCTTCGTGACAC–3' (sense) and 5'–GAGATCCTGCATCTCGGAAG–3' 154 
(antisense), the primers for detection of the β3-integrin promoter region were 5'–155 
TCTCAGGCGCAGGGTCTAGAGAA–3' (sense) and 5'–156 
TCGCGGCGCCCACCGCCTGCTCTACGCT–3' (antisense).  PCR products were resolved on a 157 
2% agarose gel in the presence of RGB-4103 GelRed Nucleic Acid Stain. 158 
 159 
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Nuclear/cytosolic extraction 160 
 MDA-MB-231 cancer cells (3.0 x 105 per well) were seeded in Dulbecco’s modified 161 
Eagle’s medium/Ham’s F-12 medium supplemented with 2.5% charcoal-stripped fetal bovine 162 
serum and were allowed to attach for 24 hours.  The medium was then changed to DMEM/Ham 163 
F-12 medium contained 2.5% charcoal-stripped fetal bovine serum, and either DMSO or TGFβ 164 
(5 ng/ml) was added for 4 hours (after ± pretreatment with 20 nM leptomycin B for 24 hours or ± 165 
pretreatment with 20 μM DIM-C-pPhOH or DIM-C-pPhCO2Me.  Nuclear and cytosolic 166 
fractions were then isolated using Thermo Scientific NE-PER Nuclear and Cytoplasmic 167 
Extraction Kit (Rockford, IL) according to manufacturer’s protocol.  Fractions were then 168 
analyzed by western blot.  GAPDH and p84 were used as cytoplasmic and nuclear positive 169 
controls respectively. 170 
 171 
Immunofluorescence 172 
 MDA-MB-231 (1.0 x 105 per well) were seeded in 2-well Nunc Lab-Tek chambered 173 
B#1.0 Borosilicate coverglass slides from Thermo Scientific and were allowed to attach for 24 174 
hours.  The medium was then changed to DMEM/Ham F-12 medium contained 2.5% charcoal-175 
stripped fetal bovine serum, and either DMSO or TGFβ (5 ng/ml) was added for 4 hours (after ± 176 
pretreatment with leptomycin B (20 nM) for 24 hours or ± pretreatment with 20 μM DIM-C-177 
pPhOH or DIM-C-pPhCO2Me.  Cells were then treated with fluorescent NR4A1 primary 178 
antibody (Nur77 (D63C5) XP®) and immunofluorescence was observed according to Cell 179 
Signaling Technology’s immunofluorescence protocol.  DAPI staining was observed using 180 
Hoechst staining according to Biotium’s Apoptotic and Necrotic assay kit following the 181 
manufacturer's protocol.  Cells were visualized by microscopy (Advanced Microscopy) and 182 
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NR4A1 localization was determined by green fluorescence.  DAPI was used to stain the nucleus 183 
and images were taken sequentially of NR4A1, DAPI, and then merged (28-30). 184 
 185 
Western blot analysis 186 
 SKBR3, MDA-MB-231, and MCF-7 cancer cells (3.0 x 105 per well) were seeded in 187 
Dulbecco’s modified Eagle’s medium/Ham’s F-12 medium supplemented with 2.5% charcoal-188 
stripped fetal bovine serum and were allowed to attach for 24 hours.  Cells were transfected with 189 
100 nm of siβ1-integrin, siNR4A1, siSp1, or sip300 for 72 hours or treated with various C-DIM 190 
compounds.  Cell lysates were analyzed by western blot as described previously (28-30). 191 
 192 
Small interfering RNA interference assay 193 
 SiRNA experiments were conducted as described previously (28-30).  The siRNA 194 
complexes used in the study are as follows:  siGL2-5':  CGU ACG CGG AAU ACU UCG A; 195 
siNR4A1:  SASI_Hs02_00333289[1], SASI_Hs02_00333290[2]; siβ1-integrin:  196 
SASI_Hs02_00333437[1], SASI_Hs01_00159474; siSp1:SASI_Hs02_003; sip300:  197 
SASI_Hs01_00052818. 198 
 199 
TNBC orthotopic xenograft studies 200 
 Female BALB/c nude mice (6–8 weeks old) were obtained (Charles River Laboratory, 201 
Wilmington, MA, USA) maintained and treated as previously described (30).  Tumor volumes 202 
and tumor weights were determined as previously described (30).  Tumor lysates were obtained 203 
and analyzed by western blots. 204 
Statistical analysis 205 
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 Statistical significance of differences between the treatment groups was determined by 206 
Student's t-test.  The results are expressed as means with error bars representing 95% CIs for at 207 
least three experiments for each group unless otherwise indicated.  A P value < 0.05 was 208 
considered statistically significant.  All statistical tests were two sided. 209 
 210 
Results 211 
NR4A1 regulates β1-integrin expression 212 
 β1-Integrin is expressed in ER-positive MCF-7, ER-negative MDA-MB-231, and erbB2-213 
overexpressing SKBR3 breast cancer cells, and knockdown of NR4A1 (siNR4A1) by RNAi 214 
(RNA interference) decreased expression of β1-integrin protein and mRNA (Fig. 1A).  Previous 215 
studies identified 1,1-bis(3'-indolyl)-1-(p-hydroxyphenyl)methane (DIM-C-pPhOH; C-DIM8) 216 
and 1,1-bis(3'-indolyl)-1-(p-carboxymethylphenyl)methane (DIM-C-pPhCO2Me; C-DIM14) as 217 
NR4A1 ligands that act as antagonists in breast and other cancer cell lines (25-30), and both 218 
compounds also decreased expression of β1-integrin protein (Fig. 1B) and mRNA (Fig. 1C) in 219 
MCF-7, MDA-MB-231 and SKBR3 cells.  Moreover, western blot analysis of tumor lysates 220 
from mice bearing MDA-MB-231 cells (orthotopic) (30) showed that DIM-C-pPhCO2Me 221 
significantly decreases β1-integrin protein expression (Fig. 1D).  β1-Integrin regulates 222 
phosphorylation of FAK (p-FAK), and transfection of MCF-7, MDA-MB-231 and SKBR3 cells 223 
with siNR4A1 (Fig. 2A) or treatment with DIM-CpPhOH (Fig. 2B) or DIM-C-pPhCO2Me (Fig. 224 
2C) decreased phosphorylation of FAK.  In addition, results from the in vivo orthotopic study 225 
(30) showed that p-FAK is decreased in tumors from mice bearing MDA-MB-231 cells and 226 
treated with DIM-C-pPhCO2Me (Fig. 2D).  Fibronectin-induced cell adhesion is also a 227 
prototypical β1-integrin-regulated response, and cell adhesion was significantly decreased in 228 
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MCF-7, MDA-MB-231 and SKBR3 after transfection with siNR4A1 (Fig. 2E) or after treatment 229 
with DIM-C-pPhOH or DIM-C-pPhCO2Me (Fig. 2F).  As a positive control, we showed that 230 
knockdown of β1-integrin (siβ1-integrin) by RNA also decreased cell adhesion (Fig. 2E) (see 231 
Suppl. Fig. S1).   232 
 233 
Mechanisms of NR4A1-regulation of β1-integrin and β3-integrin 234 
 NR4A1 regulates gene expression through direct interactions with genomic NGFBα 235 
response elements (NBRE) and Nur response elements (NuRE) or by interactions with 236 
specificity protein 1 (Sp1) bound to GC-rich promoter elements (32, 33).  NBRE and NuRE were 237 
not identified in the β1-integrin promoter, whereas two GC-rich sequences were located at -760 238 
and -676 in the proximal region of the β1-integrin promoter (Fig. 3A).  Previous studies show 239 
that NR4A1, Sp1 and the nuclear coregulatory gene p300 interact with the GC-rich region of the 240 
survivin promoter to regulate survivin gene expression (25).  Using the more aggressive SKBR3 241 
and MDA-MB-231 cells as models, cells were treated with dimethyl sulfoxide (DMSO), DIM-C-242 
pPhOH or DIM-C-pPhCO2Me and analyzed in a chromatin immunoprecipitation (ChIP) assay 243 
using primers targeted to the GC-rich region of the β1-integrin promoter.  The results show that 244 
pol II, NR4A1, Sp1 and p300 interact with the GC-rich promoter regions and after treatment 245 
with DIM-C-pPhOH or DIM-C-pPhCO2Me for 24 hr, the band for pol II was decreased in both 246 
cell lines (Fig. 3A) and this was consistent with decreased β1-integrin expression.  Ligand-247 
induced inactivation of NR4A1 also decreased NR4A1 binding to the promoter; however, 248 
changes in the Sp1 and p300 bands were somewhat variable and dependent on cell context and 249 
ligand.  For example, the loss of p300 was observed in SKBR3 but not MDA-MB-231 cells, and 250 
it is possible that p300 may be interacting with the trans-acting factors in the proximal region of 251 
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the β1-integrin promoter.  We further investigated the role of Sp1 and p300 in regulating β1-252 
integrin expression in SKBR3 and MDA-MB-231 cells by RNAi, and knockdown of Sp1 (siSp1) 253 
and p300 (sip300) also decreased β1-integrin expression (Fig. 3B), suggesting that like survivin 254 
(25), NR4A1 regulates β1-integrin expression through a NR4A1/p300/Sp1 complex.  P300 255 
knockdown also decreases Sp1 expression, suggesting that p300 plays a role in regulating 256 
expression of this gene.  These results do not exclude a role for other factors in NR4A1 257 
regulation of β1-integrin and this is currently being investigated.   258 
 Previous reports show that inhibition of β1-integrin by RNAi or other β1-integrin 259 
inhibitors increases expression of β3-integrin resulting in enhanced metastasis (34-36).  The β3-260 
integrin promoter is also GC-rich (37) and therefore we investigated the possible regulation of 261 
β3-integrin by NR4A1.  Western blot analysis showed that constitutive β3-integrin protein levels 262 
were barely detectable and remained low after treatment with C-DIM/NR4A1 antagonists or 263 
siNR4A1 (Fig. 3C), whereas knockdown of β1-integrin by RNAi increased β3-integrin protein 264 
as previously reported (36).  There was a more robust expression of β3-integrin mRNA in MDA-265 
MB-231 and SKBR3 cells and transfection of siNR4A1 or treatment with C-DIM/NR4A1 266 
antagonists significantly decreased β3-integrin mRNA levels (Fig. 3D).  ChIP assays showed 267 
that NR4A1, Sp1 and p300 bound the proximal GC-rich region of the β3-integrin gene and 268 
treatment with DIM-C-pPhOH or DIM-C-pPhCO2Me decreased binding of pol II, NR4A1 and 269 
Sp1 but differentially affected p300 binding to the promoter.  In addition, we also observed that 270 
knockdown of Sp1 (siSp1) or p300 (sip300) in MDA-MB-231 and SKBR3 cells decreased β3-271 
integrin mRNA levels (Fig. 3E).  These results demonstrate that NR4A1 regulates both β1- and 272 
β3-integrin expression and in contrast to β1-inegrin-specific inhibitors, NR4A1 antagonists 273 
downregulate expression of both β1- and β3-integrin. 274 
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 275 
Migration of MDA-MB-231 and SKBR3 cells:  role of NR4A1 and β1-integrin 276 
 Both MDA-MB-231 and SKBR3 cells undergo migration (constitutive) in a Boyden 277 
chamber assay in the absence of a stimulus.  Transfection of these cells with siNR4A1 (Fig. 4A) 278 
or siβ1-integrin (Fig. 4B) decreased migration of both cell lines and similar results were 279 
observed with two oligonucleotides targeting NR4A1 and β1-integrin.  Treatment of SKBR3 and 280 
MDA-MB-231 cells with DIM-C-pPhOH (CDIM8) or DIM-C-pPhCO2Me (CDIM14) also 281 
decreased migration (Fig. 4C), and the effects of DIM-C-pPhOH as an inhibitor of cell migration 282 
was not affected by cotreatment with leptomycin B (LMB), confirming that the inhibitory effects 283 
of this NR4A1 antagonist did not require nuclear export (25).  We also investigated the role of 284 
NR4A1 in mediating DIM-C-pPhCO2Me-dependent inhibition of migration of MDA-MB-231 285 
and SKBR3 cells by knocking down NR4A1 and then treating with the NR4A1 antagonist DIM-286 
C-pPhcO2Me (Fig. 4E).  Treatment of the NR4A1-depleted cells with DIM-C-pPhCO2Me 287 
resulted in minimal inhibition of cell migration.  Similar results were observed after treatment of 288 
β1-integrin-depleted cells with DIM-C-pPhCO2Me and we also observed that DIM-C-pPhOH 289 
did not inhibit invasion in cells depleted of NR4A1 or β1-integrin (Suppl. Fig. S2).  This would 290 
suggest that induction of β3-integrin after knockdown of β1-integrin (Fig. 3B) does not play a 291 
very significant role in cell migration using the Boyden chamber assay.  Thus, inhibition of 292 
breast cancer cell migration by C-DIMs/NR4A1 antagonists is both NR4A1- and β1-integrin-293 
dependent and consistent with regulation of β1-integrin by NR4A1.  Overexpression of β1-294 
integrin in SKBR3 and MDA-MB-231 cells slightly increases cell migration and in NR4A1-295 
depleted cells which exhibit decreased migration, overexpression of β1-integrin significantly 296 
reverses this response (Fig. 4F).  In addition, NR4A1 ligand-mediated inhibition of breast cancer 297 
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cell migration was also rescued by β1-integrin overexpression (Fig. 4G), further confirming that 298 
β1-integrin-mediated migration is NR4A1-dependent.  Thus, the constitutive or basal migration 299 
of SKBR3 and MDA-MB-231 cells in the absence of endogenous stimuli is linked to nuclear 300 
NR4A1 regulation of β1-integrin. 301 
 302 
TGFβ-induced migration of MDA-MB-231 cells:  role of extranuclear NR4A1 303 
 A recent study reported that TGFβ-induced migration of MDA-MB-231 cells was also 304 
NR4A1-dependent and involved a pathway associated with SMAD7 degradation resulting in 305 
activation of TGFβR1 (31).  Treatment of MDA-MB-231 cells with 5 ng/ml TGFβ significantly 306 
induced cell migration (Fig. 5A) as previously described (31), and knockdown of NR4A1 or 307 
treatment with DIM-C-pPhOH or DIM-C-pPhCO2Me blocked TGFβ-induced migration and 308 
significantly decreased overall migration, similar to that observed after knockdown of NR4A1 or 309 
treatment with the NR4A1 antagonists alone (Figs. 4A-4C).  TGFβ-induced migration was 310 
inhibited after cotreatment with the TGFβR1 inhibitor ALK5i and also the nuclear export 311 
inhibitor LMB and ALK5i had no effect on endogenous cell migration (data not shown).  312 
Analysis of cytosolic and nuclear extracts show that TGFβ induced expression and nuclear 313 
export of NR4A1 which was blocked by LMB (Fig. 5B) indicating that TGFβ-induced migration 314 
requires cytosolic NR4A1, whereas constitutive migration which is not inhibited by ALK5i is 315 
due to nuclear NR4A1-dependent regulation of β1-integrin.  We also examined SMAD7 316 
expression and observed minimal endogenous expression in MDA-MB-231 and SKBR3 cells 317 
and TGFβ increased SMAD7 only in SKBR3 cells (Fig. 5C).  In contrast, cotreatment with 318 
TGFβ plus LMB, CDIM8 or CDIM14 dramatically increased SMAD7 protein expression of both 319 
cell lines, suggesting nuclear localization of NR4A1 inhibits degradation of SMAD7 which is a 320 
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cytosolic protein.  These results are consistent with previous studies, suggesting that NR4A1 321 
(cytosolic) plays a role in proteasome-dependent degradation of SMAD7 (31).  Immunostaining 322 
of NR4A1 in MDA-MB-231 cells confirms that NR4A1 is nuclear, and treatment with TGFβ 323 
induces nuclear export of this receptor and this is blocked by LMB (Fig. 5C).   324 
 Since C-DIM/NR4A1 antagonists act through binding nuclear NR4A1, we examined the 325 
effects of short term (4 hr) treatment of MDA-MB-231 with DIM-C-pPhOH or DIM-C-326 
pPhCO2Me on TGFβ-induced migration.  Like LMB, both compounds blocked TGFβ-induced 327 
migration (Fig. 6A) and this was accompanied by inhibition of TGFβ-induced nuclear export of 328 
NR4A1 (Fig. 6B) and paralleled results observed for LMB (Figs. 5A and 5B).  The inhibitory 329 
effects observed after treatment with the C-DIM/NR4A1 ligands for 4 hr was not due to 330 
decreased β1-integrin expression (Fig. 6C), suggesting that bound NR4A1 was resistant to 331 
TGFβ-induced nuclear export and the factors that regulate nuclear export are currently being 332 
investigated.  A previous report showed that TGFβ-induced NR4A1 interacts with axin 2 and 333 
other factors (e.g. E3 ligases Arkadia and RNF12) to form a polyubiquitination complex (31), 334 
and after treatment of MDA-MB-231 cells with TGFβ, LMB, C-DIMs and their combinations, 335 
western blot analysis of the cytosolic fraction immunoprecipitated with axin 2 antibodies gave a 336 
strong band for NR4A1 only in cells treated with TGFβ alone (Fig. 6D).  In contrast, treatment 337 
with DIM-C-pPhOH, DIM-C-pPhCO2Me or LMB which inhibit TGFβ-induced nuclear export 338 
of NR4A1 resulted in decreased intensities of cytosolic NR4A1 bands associated with the axin 2 339 
antibody immunoprecipitates.  The results demonstrate that NR4A1plays an important role in 340 
breast cancer cell migration by regulation of β1-integrin (endogenous activity) and TGFβ-341 
induced migration which is dependent on NR4A1 nuclear export (Fig. 6E).   342 
 343 
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Discussion 344 
 The NR4A family of orphan nuclear receptors NR4A1, NR4A2 and NR4A3 were 345 
initially identified as stress-induced immediate early genes with a characteristic domain structure 346 
observed for nuclear receptors.  NR4A receptors have both unique and overlapping functions and 347 
there is increasing evidence that they play an important role in cellular homeostasis and diseases 348 
associated with metabolism, cardiovascular and neurological functions, inflammation and the 349 
immune system (38-40).  Endogenous ligands for NR4A1 have not been identified; however, 350 
synthetic ligands that are structurally related to cytosporone B have been developed (41-43) and 351 
have potential clinical applications.  For example, ethyl[2,3,4-trimethoxy-6-(i-352 
octanoyl)phenyl]acetate is an NR4A1 ligand that acts as a receptor antagonist to decrease 353 
NR4A1-dependent hepatic gluconeogenesis and lower blood glucose levels in a rodent model for 354 
type 2 diabetes (43).  NR4A1 is also overexpressed in solid tumors including both ER-positive 355 
and ER-negative breast tumors and is a negative prognostic factor for lung, colon, breast cancer 356 
patients (26, 31, 44). 357 
 Initial studies targeting NR4A1 for cancer chemotherapy showed that cell death observed 358 
in some cancer cell lines treated with several apoptosis agents was due to nuclear export of 359 
NR4A1 and the subsequent interactions of NR4A1 with bcl-2 to form a pro-apoptotic complex 360 
that disrupted mitochondria (45, 46).  The pro-apoptotic effects were also observed using 361 
peptides and paclitaxel that mimic NR4A1 interactions with bcl-2 (42, 47).  Studies in this 362 
laboratory have identified C-DIMs as NR4A1 ligands that act as antagonists in cancer cell lines, 363 
and previous studies have demonstrated that C-DIM/NR4A1 antagonists inhibit growth and 364 
induce cell death through inactivation of nuclear NR4A1-dependent pro-oncogenic pathways in 365 
pancreatic, lung, colon, kidney and breast cancer cells lines (24-30).   366 
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 A recent report showed that high expression of NR4A1 in breast tumors correlated with 367 
decreased relapse-free survival and this was linked to the role of NR4A1 in TGFβ and 368 
TGFβ/cytokine-induced migration/invasion and metastasis (31).  Results of ongoing genomic 369 
and functional studies in several cancer cell lines identified β-integrin as a possible NR4A1-370 
regulated pro-migration/invasion gene and this correlated with previous in vivo studies showing 371 
that β1-integrin was important for metastasis of mammary tumors overexpressing the erbB2 372 
oncogene (9, 21-23).  Results in Figures 1, 2, and 4 demonstrate that knockdown of NR4A1 or 373 
treatment with the NR4A1 antagonists DIM-C-pPhOH and DIM-C-pPhCO2Me decreased 374 
expression of β1-integrin protein and mRNA and β1-integrin-dependent responses in MCF7, 375 
MDA-MB-231 and SKBR3 cells and also inhibited migration of the latter two cell lines.   376 
 The mechanism of NR4A1 regulation of β-integrin in SKBR3 and MDA-MB-231 cells 377 
did not involve direct binding to cis-acting genomic sequences but through an indirect 378 
mechanism in which NR4A1/p300 act as a coregulatory complex to activate Sp1-regulated 379 
genes.  The ChIP assays show that NR4A1, Sp1 and p300 interacted at the GC-rich region of the 380 
β1-integrin gene promoter (Fig. 3), and knockdown of anyone of these factors or treatment with 381 
C-DIM/NR4A1 antagonists resulted in decreased β1-integrin expression.  These results are 382 
similar to that previously observed for NR4A1/p300/Sp1-mediated regulation of survivin in 383 
pancreatic cancer cells (25) and are consistent with other reports showing that other nuclear 384 
receptors also regulate expression of other Sp-dependent genes through NR4A1/Sp1 complexes 385 
(48-50).  Previous studies show that knockdown or inhibition of β1-integrin in breast cancer cells 386 
results in the expression of β3-integrin and this "integrin-switching" enhances TGFβ-induced 387 
metastasis (34-36) and this presents a problem for applications of β1-integrin inhibitors in 388 
treatment of breast cancer.  Like β1-integrin, the 5'-promoter region of the β3-integrin gene 389 
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contains GC-rich sequences (37) and our results demonstrates that NR4A1 also regulates β3-390 
integrin expression, and NR4A1 antagonists or NR4A1 knockdown decreases expression of both 391 
genes (Fig. 3).  Thus, coregulation of β1- and β3-integrin by NR4A1 negates the "integrin-392 
switching" phenomena (34-36) and further demonstrates that the C-DIM/NR4A1 antagonists 393 
represent a novel therapeutic approach for inhibiting β1/β3-integrin-induced signaling and 394 
metastasis in breast cancer cells. 395 
 MDA-MB-231 and SKBR3 cells readily migrate in the absence of TGFβ or cytokine 396 
stimulus, and results of RNAi studies show that inhibition of cell migration by C-DIM/NR4A1 397 
antagonists was observed only in cells expressing NR4A1 or β1-integrin (Fig. 4).  Moreover, 398 
since the inhibitory effects of C-DIMs were similar in the presence or absence of the nuclear 399 
export inhibitor LMB (Fig. 4F), our results indicate that constitutive migration of these cells was 400 
due to nuclear NR4A1-dependent regulation of β1-integrin.  This is also supported by the 401 
observation that the TGFβ receptor inhibitor ALK5i inhibits TGFβ-induced migration but does 402 
not affect the high rate of constitutive migration of MDA-MB-231 cells (Fig. 5A).  A recent 403 
study showed that NR4A1 was also required for TGFβ-induced migration of MDA-MB-231 and 404 
other cell lines and this was due to interactions of NR4A1, axin 2 and E3 ligases which enhanced 405 
SMAD7 degradation, resulting in activation of the TGFβR1 pathway (31).  We also observed 406 
that TGFβ induced NR4A1 expression and migration of MDA-MB-231 cells; however, the key 407 
essential element in this pathway was that TGFβ induced nuclear export of NR4A1 (Figs. 5B, 408 
5D and 6C).  Moreover, inhibition of nuclear export by the NR4A1 ligands (DIM-C-pPhOH or 409 
DIM-C-pPhcO2Me) or LMB also blocked TGFβ-induced migration and enhanced SMAD7 410 
expression (Fig. 5C).  Previous studies on SMAD7 degradation in MDA-MB-231 cells used 411 
transfected FLAG-SMAD7 (31), whereas in this study, we observed low to non-detectable 412 
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SMAD7 expression in MDA-MBA-231 and SKBR3 cells.  However, LMB, DIM-C-pPhOH and 413 
DIM-C-pPhCO2Me which prevent NR4A1 export also increased SMAD7 expression in cells 414 
cotreated with these compounds plus TGFβ (Fig. 5C) and this is consistent with a role for 415 
cytosolic NR4A1 in SMAD7 degradation as previously reported (31).  Thus, TGFβ-induced 416 
migration of MDA-MB-231 cells is due to nuclear export of NR4A1 and the C-DIM/NR4A1 417 
antagonist block this pathway presumably by inhibiting factors/pathways required for nuclear 418 
export and these are currently being investigated.   419 
 In summary, results of this study show that nuclear NR4A1 regulates β1-integrin 420 
expression in breast cancer cells, and C-DIM/NR4A1 antagonists inhibit expression of β1-421 
integrin and β1-integrin-mediated responses including cell migration and the antagonists also 422 
inhibit NR4A1-regulated expression of β3-integrin.  In contrast, TGFβ-induced migration of 423 
MDA-MB-231 cells requires nuclear export of NR4A1 which is inhibited not only by LMB but 424 
also by C-DIM/NR4A1 antagonists.  Thus, constitutive and TGFβ-induced migration are 425 
dependent on nuclear and extranuclear NR4A1, respectively, and the C-DIM/NR4A1 antagonists 426 
inhibit both pathways by decreasing NR4A1-dependent expression of β1-integrin and by 427 
inhibition of TGFβ-induced nuclear export of NR4A1 (Fig. 6E).  This study expands on the pro-428 
oncogenic functions of NR4A1 and indicates that C-DIM compounds and other NR4A1 429 
antagonists represent an important new class of mechanism-based anticancer drugs for treating 430 
patients with tumors overexpressing this receptor.   431 
 432 
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Figures  597 
Fig. 1. NR4A1 regulates β1-integrin expression in breast cancer cells and tumors.  (A) Breast 598 
cancer cells were transfected with siNR4A1 and cell extracts were analyzed for protein 599 
and mRNA expression by western blots or real time PCR, respectively, as outlined in the 600 
Materials and Methods.  Breast cancer cells were treated with DMSO, DIM-C-pPhOH or 601 
DIM-C-pPhCO2Me for 24 hr and extracts were analyzed for protein (B) or mRNA (C) 602 
levels by western blots and real time PCR, respectively, as outlined in the Materials and 603 
Methods.  (D) Cell lysates from tumors (MDA-MB-231 orthotopic) (30) derived from 604 
animals treated with corn oil (control) or DIM-C-pPhCO2Me (C-DIM-14; 40 mg/kg/d) 605 
were analyzed by western blots and decreased protein expression was determined and 606 
normalized the β-actin protein loading control.  Quantified data are presented as means ± 607 
SE (at least 3 replicates) and significant (P<0.05) decreases are indicated (*).   608 
Fig. 2. NR4A1 regulates β1-integrin-dependent responses.  Breast cancer cells were transfected 609 
with siNR4A1 (A), treated with DMSO and DIM-C-pPhOH (B) or DIM-C-pPhCO2Me 610 
(C) for 24 hr, and whole cell lysates were analyzed by western blots as outlined in the 611 
Materials and Methods.  (D) Tumor lysates from mice (MDA-MB-231 orthotopic-612 
derived (30) treated with corn oil or DIM-C-pPhCO2Me (40 mg/kg/d) were analyzed by 613 
western blots and quantitated as outlined in Figure 1D.  The effects of siNR4A1 and siβ1-614 
integrin (E) or DIM-C-pPhOH and DIM-C-pPhCO2Me (F) on fibronectin-induced 615 
adhesion of breast cancer cells was determined as outlined in the Materials and Methods.  616 
Results (D-F) are means ± SE (at least 3 replicates) and a significant (P<0.05) decrease 617 
indicated (*).  Western blots in Figures 1 and 2 were derived from the same experiment 618 
showing effects on β1-integrin (Fig. 1) and β1-integrin-regulated responses (Fig. 2). 619 
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Fig. 3. Role of NR4A1/p300/Sp1 in regulation of β1- and β3-integrin.  (A) Analysis of polII, 620 
NR4A1, Sp1 and p300 binding to the β1-integrin promoter was determined in a ChIP 621 
assay using primers as indicated.  (B) Cells were treated with oligonucleotides that 622 
knockdown Sp1 (siSp1) and p300 (sip300), and whole cell lysates were analyzed by 623 
western blots as outlined in the Materials and Methods.  (C) Cells were transfected with 624 
siNR4A1 or treated with DIM-C-pPhOH (C-DIM8) or DIM-C-pPhCO2Me (C-DIM14), 625 
and whole cell lysates were analyzed by western blots as outlined in the Materials and 626 
Methods.  (D) Cells were transfected with siNR4A1 or treated with C-DIM8 or C-DIM14 627 
and effects on β3-integrin (ITGB3) mRNA levels were determined.  The treatments 628 
significantly (P<0.05) decrease mRNA levels.  (E) Analysis of polII, NR4A1, Sp1 and 629 
p300 binding to the proximal GC-rich region of the β3-integrin promoter was determined 630 
in a ChIP assay as outlined in the Materials and Methods.  (F) Cells were transfected with 631 
siSp1 and sip300 and analyzed by real time PCR for β3-integrin mRNA levels.  Both 632 
oligonucleotides significantly (P<0.05) decreased β3-integrin mRNA levels. 633 
Fig. 4. NR4A1-regulates β1-integrin-dependent breast cancer cell migration.  Cells were 634 
transfected with siNR4A1 (A), siβ1-integrin (B), or treated with DIM-C-pPhOH and 635 
DIM-C-pPhCO2Me (C), and DIM-C-pPhOH ± LMB (D), and breast cancer cell 636 
migration was determined in a Boyden chamber assay as outlined in the Materials and 637 
Methods.  (E) Cells were transfected with a non-specific oligonucleotide (siCtl), 638 
siNR4A1, siβ1-integrin and treated with DIM-C-pPhCO2Me, and cell migration was 639 
determined in a Boyden chamber assay as outlined in the Materials and Methods.  Cells 640 
were transfected with siNR4A1 alone (F) or treated with DIM-C-pPhOH/DIM-C-641 
pPhCO2Me (G) in combination with β1-integrin (ITGB1) expression plasmid, and effects 642 
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on cell migration were determined in a Boyden chamber assay as outlined in the 643 
Materials and Methods.  Results are expressed as means ± SE for at least 3 replicates for 644 
each treatment group and significantly (P<0.05) decreased migration (*) or rescue by β1-645 
integrin overexpression (**) are indicated.   646 
Fig. 5. Role of NR4A1 on TGFβ-induced migration of MDA-MB-231 cells.  (A) MDA-MB-231 647 
cells were treated with TGFβ alone for 5 hr or in combination with siNR4A1, DIM-C-648 
pPhOH and DIM-C-pPhCO2Me (24 hr treatment), LMB and ALK5i, and LMB (alone).  649 
Cell migration was determined in a Boyden chamber assay.  (B) MDA-MB-231 cells 650 
were treated with DMSO, TGFβ and LMB (alone) and in combination for 5 hr.  Nuclear 651 
and cytosolic extracts were analyzed by western blots using nuclear (p84) and cytosolic 652 
(GADPH) loading controls.  (C) Cells were treated with DMSO, TGFβ, LMB alone and 653 
TGFβ in combination with LMB, DIM-C-pPhOH (CDIM8) or DIM-C-pPhCO2Me 654 
(CDIM14) for ___ hr, and whole cell lysates were analyzed for SMAD7 expression by 655 
western blot analysis.  (D) Cells were treated with DMSO, 5 ng/ml TGFβ, LMB and 656 
LMB plus TGFβ for 5 hr and immunostained with both NR4A1 antibodies and DAPI as 657 
outlined in the Materials and Methods. 658 
Fig. 6. (A) MDA-MB-231 cells were treated with TGFβ, DIM-C-pPhOH and DIM-C-659 
pPhCO2Me alone and TGFβ plus C-DIMs for 4 hr, and cell migration was determined in 660 
a Boyden Chamber assay and immunostaining (NR4A1) and DAPI staining was 661 
determined as outlined in Figure 5C.  (B) Cells were treated as described in (Fig. 5B) and 662 
the cytosolic and nuclear extracts were further examined by western blot analyses.  (C) 663 
MDA-MB-231 cells were treated with DIM-C-pPhCO2Me or DIM-C-pPhOH for 664 
different times and whole cell lysates were analyzed by western blots for β1-integrin 665 
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expression.  (D) Cells were treated as outlined in Figure 6B and whole cell lysates were 666 
immunoprecipitated with axin 2 antibodies and analyzed by western blots.  (E) Schematic 667 
outline of the role of NR4A1 in constitutive and TGFβ-induced migration in breast 668 
cancer cells. 669 
 670 
  671 
 672 
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Correction for Hedrick et al., “NR4A1
Antagonists Inhibit 1-Integrin-
Dependent Breast Cancer Cell Migration”
Erik Hedrick,a Syng-Ook Lee,b Ravi Doddapaneni,c Mandip Singh,c Stephen Safea
Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, Texas, USAa;
Department of Food Science and Technology, Keimyung University, Daegu, Republic of Koreab; Department
of Pharmaceutics, College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee,
Florida, USAc
Volume 36, no. 9, p. 1383–1394, 2016, https://doi.org/10.1128/MCB.00912-15. Page
1385, Fig. 1: The -actin controls for the MCF-7 cell lysate analysis for panels A and B
were run on the same gel. We inadvertently used in panel A the last two -actin lanes
of panel B, left. The corrected MCF-7 -actin bands for panel A should appear as shown
below.
Page 1386, Fig. 2: The same lysates and -actin bands from Fig. 1 were used in
panels A and B, with the same problem. Therefore, the corrected MCF-7 -actin bands
for panel A should appear as shown above.
Citation Hedrick E, Lee S-O, Doddapaneni R,
Singh M, Safe S. 2017. Correction for Hedrick et
al., “NR4A1 antagonists inhibit β1-integrin-
dependent breast cancer cell migration.” Mol
Cell Biol 37:e00197-17. https://doi.org/10.1128/
MCB.00197-17.
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